<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00569192</url>
  </required_header>
  <id_info>
    <org_study_id>MAP0010-CL-P301</org_study_id>
    <nct_id>NCT00569192</nct_id>
  </id_info>
  <brief_title>A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled, Parallel Group, Study Investigating the Safety and Efficacy Over 12 Weeks Treatment Period of MAP0010 in Asthmatic Infants and Children 12 Months to 8 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the safety and efficacy of two doses of MAP0010
      versus placebo in asthmatic infants and children, 12 months to 8 years of age, over a 12-week
      treatment period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Daytime Composite Symptom Score</measure>
    <time_frame>baseline, week 12</time_frame>
    <description>The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.
The individual symptoms were scored using a four point scale:
0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms
Daily composite symptom score is based on the average of the individual symptom scores for a day. Daytime composite symptom score is defined as average of the last 5 days' daily composite symptom scores within the last 7 days immediately preceding the end day of that week. The range for the daytime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Nighttime Composite Symptom Score</measure>
    <time_frame>baseline, week 12</time_frame>
    <description>The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.
The individual symptoms were scored using a four point scale:
0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms
Nightly composite symptom score is based on the average of the individual symptom scores for the night. Nightime composite symptom score is defined as average of the last 5 days' nightly composite symptom scores within the last 7 nights immediately preceding the end day of that week. The range for the nighttime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FEV1% Predicted</measure>
    <time_frame>baseline, week 12</time_frame>
    <description>The forced expiratory volume in 1 second (FEV1) is the amount forced of air exhaled in 1 second. The percent predicted is calculated for age, gender, and height. Subjects had to perform at least 3 acceptable maneuvers into a spirometer and the largest volume from the 3 maneuvers was selected. An increase indicates an improvement (a greater volume of air expired).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PEF</measure>
    <time_frame>baseline, week 12</time_frame>
    <description>The peak expiratory flow (PEF) is the highest air flow achieved from a maximum forced expiratory maneuver measured in liters of air per minute (L/min). Subjects had to perform at least 3 acceptable maneuvers into a PEF meter. An increase indicates an improvement (a greater volume of air expired).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daytime Individual Symptom Scores</measure>
    <time_frame>baseline, week 12</time_frame>
    <description>The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.
The individual symptoms were scored using a four point scale:
0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms
Individual Daytime symptom score is defined as an average of the last 5 days' individual symptom scores within the last 7 days immediately preceding the end day of that week. A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nighttime Individual Symptom Scores</measure>
    <time_frame>baseline, week 12</time_frame>
    <description>The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.
The individual symptoms were scored using a four point scale:
0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms
Individual nighttime symptom score is defined as an average of the last 5 nights' individual symptom scores within the last 7 nights immediately preceding the end day of that week. A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">360</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>0.25mg MAP0010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo delivered by nebulization twice daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.135mg MAP0010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.135mg MAP0010</intervention_name>
    <description>0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks</description>
    <arm_group_label>0.135mg MAP0010</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.25mg MAP0010</intervention_name>
    <description>0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks</description>
    <arm_group_label>0.25mg MAP0010</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo delivered by nebulization twice daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female asthmatic children with mild to moderate persistent asthma.

          -  12 months to 8 years of age.

          -  For children age 4 to 8 years: Documented diagnosis of asthma at least 3 months prior
             to Visit 1, per NIH (EPR-3) criteria.

          -  For infants age 12 to &lt;48 months old: 2 or more wheezing episodes in past 12 months
             which lasted &gt; 1 day and affected sleep.

          -  AND with at least one major or two minor risk factors.

        Exclusion Criteria:

          -  Any other significant childhood illness/abnormality or chronic lung disease

          -  Any history of upper or lower respiratory tract infection, within 2 weeks of
             screening.

          -  Any history of acute or severe asthma attack requiring ICU admission or ventilatory
             support.

          -  Use of any corticosteroid, including inhaled, parental, intranasal, or topical
             corticosteroid within 2 weeks of screening.

          -  Any use of oral corticosteroids within 30 days of screening or prolonged use (&gt;10
             consecutive days) of oral corticosteroids, within 12 weeks of screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>MAP Pharmaceuticals</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2007</study_first_submitted>
  <study_first_submitted_qc>December 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2007</study_first_posted>
  <results_first_submitted>August 19, 2013</results_first_submitted>
  <results_first_submitted_qc>August 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 23, 2013</results_first_posted>
  <last_update_submitted>December 9, 2013</last_update_submitted>
  <last_update_submitted_qc>December 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>asthmatic children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo delivered by nebulization twice daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>0.135 mg MAP0010</title>
          <description>0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>0.25 mg MAP0010</title>
          <description>0.125mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="125"/>
                <participants group_id="P3" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="105"/>
                <participants group_id="P3" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo delivered by nebulization twice daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>0.135 mg MAP0010</title>
          <description>0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>0.25 mg MAP0010</title>
          <description>0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="111"/>
            <count group_id="B2" value="125"/>
            <count group_id="B3" value="124"/>
            <count group_id="B4" value="360"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.5" spread="2.17"/>
                    <measurement group_id="B2" value="4.4" spread="2.33"/>
                    <measurement group_id="B3" value="4.2" spread="2.27"/>
                    <measurement group_id="B4" value="4.4" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.0" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="B2" value="4.0" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="B3" value="4.0" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="B4" value="4.0" lower_limit="1" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Daytime Composite Symptom Score</title>
        <description>The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.
The individual symptoms were scored using a four point scale:
0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms
Daily composite symptom score is based on the average of the individual symptom scores for a day. Daytime composite symptom score is defined as average of the last 5 days' daily composite symptom scores within the last 7 days immediately preceding the end day of that week. The range for the daytime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.</description>
        <time_frame>baseline, week 12</time_frame>
        <population>Intent-to-treat includes all randomized patients who have received at least one dose of study drug and have baseline and at least one post treatment efficacy assessment available.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo delivered by nebulization twice daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.135 mg MAP0010</title>
            <description>0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>0.25 mg MAP0010</title>
            <description>0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daytime Composite Symptom Score</title>
          <description>The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.
The individual symptoms were scored using a four point scale:
0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms
Daily composite symptom score is based on the average of the individual symptom scores for a day. Daytime composite symptom score is defined as average of the last 5 days' daily composite symptom scores within the last 7 days immediately preceding the end day of that week. The range for the daytime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.</description>
          <population>Intent-to-treat includes all randomized patients who have received at least one dose of study drug and have baseline and at least one post treatment efficacy assessment available.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.73" spread="1.406"/>
                    <measurement group_id="O2" value="2.96" spread="1.329"/>
                    <measurement group_id="O3" value="2.87" spread="1.383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="1.722"/>
                    <measurement group_id="O2" value="-1.77" spread="1.618"/>
                    <measurement group_id="O3" value="-1.56" spread="1.591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FEV1% Predicted</title>
        <description>The forced expiratory volume in 1 second (FEV1) is the amount forced of air exhaled in 1 second. The percent predicted is calculated for age, gender, and height. Subjects had to perform at least 3 acceptable maneuvers into a spirometer and the largest volume from the 3 maneuvers was selected. An increase indicates an improvement (a greater volume of air expired).</description>
        <time_frame>baseline, week 12</time_frame>
        <population>The modified-intent-to-treat population includes all randomized patients who were deemed capable of spirometry measurements at baseline and at least at one of the post treatment visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo delivered by nebulization twice daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.135 mg MAP0010</title>
            <description>0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>0.25 mg MAP0010</title>
            <description>0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FEV1% Predicted</title>
          <description>The forced expiratory volume in 1 second (FEV1) is the amount forced of air exhaled in 1 second. The percent predicted is calculated for age, gender, and height. Subjects had to perform at least 3 acceptable maneuvers into a spirometer and the largest volume from the 3 maneuvers was selected. An increase indicates an improvement (a greater volume of air expired).</description>
          <population>The modified-intent-to-treat population includes all randomized patients who were deemed capable of spirometry measurements at baseline and at least at one of the post treatment visits.</population>
          <units>percentage of predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.96" spread="18.646"/>
                    <measurement group_id="O2" value="91.20" spread="17.713"/>
                    <measurement group_id="O3" value="93.00" spread="17.305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="13.068"/>
                    <measurement group_id="O2" value="4.14" spread="12.845"/>
                    <measurement group_id="O3" value="0.36" spread="16.657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Nighttime Composite Symptom Score</title>
        <description>The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.
The individual symptoms were scored using a four point scale:
0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms
Nightly composite symptom score is based on the average of the individual symptom scores for the night. Nightime composite symptom score is defined as average of the last 5 days' nightly composite symptom scores within the last 7 nights immediately preceding the end day of that week. The range for the nighttime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.</description>
        <time_frame>baseline, week 12</time_frame>
        <population>Intent-to-treat includes all randomized patients who have received at least one dose of study drug and have baseline and at least one post treatment efficacy assessment available.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo delivered by nebulization twice daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.135 mg MAP0010</title>
            <description>0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>0.25 mg MAP0010</title>
            <description>0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nighttime Composite Symptom Score</title>
          <description>The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.
The individual symptoms were scored using a four point scale:
0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms
Nightly composite symptom score is based on the average of the individual symptom scores for the night. Nightime composite symptom score is defined as average of the last 5 days' nightly composite symptom scores within the last 7 nights immediately preceding the end day of that week. The range for the nighttime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.</description>
          <population>Intent-to-treat includes all randomized patients who have received at least one dose of study drug and have baseline and at least one post treatment efficacy assessment available.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.71" spread="1.393"/>
                    <measurement group_id="O2" value="2.97" spread="1.466"/>
                    <measurement group_id="O3" value="2.82" spread="1.349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.47" spread="1.572"/>
                    <measurement group_id="O2" value="-1.82" spread="1.907"/>
                    <measurement group_id="O3" value="-1.59" spread="1.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PEF</title>
        <description>The peak expiratory flow (PEF) is the highest air flow achieved from a maximum forced expiratory maneuver measured in liters of air per minute (L/min). Subjects had to perform at least 3 acceptable maneuvers into a PEF meter. An increase indicates an improvement (a greater volume of air expired).</description>
        <time_frame>baseline, week 12</time_frame>
        <population>The modified-intent-to-treat population includes all randomized patients who were deemed capable of spirometry measurements at baseline and at least at one of the post treatment visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo delivered by nebulization twice daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.135 mg MAP0010</title>
            <description>0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>0.25 mg MAP0010</title>
            <description>0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PEF</title>
          <description>The peak expiratory flow (PEF) is the highest air flow achieved from a maximum forced expiratory maneuver measured in liters of air per minute (L/min). Subjects had to perform at least 3 acceptable maneuvers into a PEF meter. An increase indicates an improvement (a greater volume of air expired).</description>
          <population>The modified-intent-to-treat population includes all randomized patients who were deemed capable of spirometry measurements at baseline and at least at one of the post treatment visits.</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170.94" spread="49.343"/>
                    <measurement group_id="O2" value="163.39" spread="52.881"/>
                    <measurement group_id="O3" value="165.34" spread="49.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="44.544"/>
                    <measurement group_id="O2" value="20.10" spread="45.444"/>
                    <measurement group_id="O3" value="15.02" spread="45.306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daytime Individual Symptom Scores</title>
        <description>The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.
The individual symptoms were scored using a four point scale:
0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms
Individual Daytime symptom score is defined as an average of the last 5 days' individual symptom scores within the last 7 days immediately preceding the end day of that week. A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.</description>
        <time_frame>baseline, week 12</time_frame>
        <population>Intent-to-treat includes all randomized patients who have received at least one dose of study drug and have baseline and at least one post treatment efficacy assessment available.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo delivered by nebulization twice daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.135 mg MAP0010</title>
            <description>0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>0.25 mg MAP0010</title>
            <description>0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daytime Individual Symptom Scores</title>
          <description>The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.
The individual symptoms were scored using a four point scale:
0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms
Individual Daytime symptom score is defined as an average of the last 5 days' individual symptom scores within the last 7 days immediately preceding the end day of that week. A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.</description>
          <population>Intent-to-treat includes all randomized patients who have received at least one dose of study drug and have baseline and at least one post treatment efficacy assessment available.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cough: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="0.544"/>
                    <measurement group_id="O2" value="1.21" spread="0.490"/>
                    <measurement group_id="O3" value="1.18" spread="0.582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough: Change from Baseline at week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.734"/>
                    <measurement group_id="O2" value="-0.68" spread="0.705"/>
                    <measurement group_id="O3" value="-0.58" spread="0.664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wheeze: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="0.591"/>
                    <measurement group_id="O2" value="0.91" spread="0.546"/>
                    <measurement group_id="O3" value="0.88" spread="0.550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wheeze: Change from Baseline at week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.615"/>
                    <measurement group_id="O2" value="-0.58" spread="0.563"/>
                    <measurement group_id="O3" value="-0.49" spread="0.589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shortness of Breath: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="0.557"/>
                    <measurement group_id="O2" value="0.84" spread="0.612"/>
                    <measurement group_id="O3" value="0.81" spread="0.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shortness of Breath: Change from Baseline at Wk 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.635"/>
                    <measurement group_id="O2" value="-0.51" spread="0.632"/>
                    <measurement group_id="O3" value="-0.49" spread="0.626"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nighttime Individual Symptom Scores</title>
        <description>The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.
The individual symptoms were scored using a four point scale:
0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms
Individual nighttime symptom score is defined as an average of the last 5 nights' individual symptom scores within the last 7 nights immediately preceding the end day of that week. A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.</description>
        <time_frame>baseline, week 12</time_frame>
        <population>Intent-to-treat includes all randomized patients who have received at least one dose of study drug and have baseline and at least one post treatment efficacy assessment available.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo delivered by nebulization twice daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.135 mg MAP0010</title>
            <description>0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>0.25 mg MAP0010</title>
            <description>0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nighttime Individual Symptom Scores</title>
          <description>The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.
The individual symptoms were scored using a four point scale:
0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms
Individual nighttime symptom score is defined as an average of the last 5 nights' individual symptom scores within the last 7 nights immediately preceding the end day of that week. A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.</description>
          <population>Intent-to-treat includes all randomized patients who have received at least one dose of study drug and have baseline and at least one post treatment efficacy assessment available.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cough: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="0.528"/>
                    <measurement group_id="O2" value="1.20" spread="0.495"/>
                    <measurement group_id="O3" value="1.17" spread="0.565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough: Change from Baseline at week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.663"/>
                    <measurement group_id="O2" value="-0.69" spread="0.720"/>
                    <measurement group_id="O3" value="-0.61" spread="0.638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wheeze: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.563"/>
                    <measurement group_id="O2" value="0.94" spread="0.592"/>
                    <measurement group_id="O3" value="0.90" spread="0.548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wheeze: Change from Baseline at week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.594"/>
                    <measurement group_id="O2" value="-0.57" spread="0.704"/>
                    <measurement group_id="O3" value="-0.51" spread="0.603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shortness of Breath: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="0.543"/>
                    <measurement group_id="O2" value="0.83" spread="0.622"/>
                    <measurement group_id="O3" value="0.75" spread="0.569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shortness of Breath: Change from Baseline at Wk 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.549"/>
                    <measurement group_id="O2" value="-0.56" spread="0.690"/>
                    <measurement group_id="O3" value="-0.47" spread="0.566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All randomized patients who received at least one dose of study drug and who have at least one post dosing safety evaluation were included in the adverse event analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo delivered by nebulization twice daily for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>0.135 mg MAP0010</title>
          <description>0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>0.25 mg MAP0010</title>
          <description>0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia Necrotising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infections</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP, Scientific Affairs</name_or_title>
      <organization>MAP Pharmaceuticals Inc., a wholly owned subsidiary of Allergan</organization>
      <phone>650-386-3100</phone>
      <email>dkellerman@mappharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

